Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: J Thorac Oncol. 2020 Jun 13;15(10):1611–1623. doi: 10.1016/j.jtho.2020.05.021

Figure 5. — Drug screen for MEK and BRAF inhibitors. A) H2087 (BRAF L597V mutation); B) H1755 (BRAF G469A mutation); C) H1395 (BRAF G469A mutation); D) HCC364 (BRAF V600E mutation); E) H1648 (BRAF wild-type); F) Relative IC50 of MEK and BRAF inhibitors for comparison between BRAF mutant and BRAF wild type cell lines.

Figure 5. — Drug screen for MEK and BRAF inhibitors. A) H2087 (BRAF L597V mutation); B) H1755 (BRAF G469A mutation); C) H1395 (BRAF G469A mutation); D) HCC364 (BRAF V600E mutation); E) H1648 (BRAF wild-type); F) Relative IC50 of MEK and BRAF inhibitors for comparison between BRAF mutant and BRAF wild type cell lines.